Tag Archives: healthcare

Lumanity Expands U.S. Life Sciences Consulting Capability with the Acquisition of Clarion

Arsenal Capital Partners

Enhanced strategic consulting capabilities supporting products throughout their lifecycles

November 8, 2022

New York, NY- Lumanity, a global leader in accelerating and optimizing access to medical advances, announced the acquisition of Clarion Healthcare (“Clarion”), a Boston-based life science consultancy with a 20-year history of being a trusted advisor for biopharma clients in solving their most complex commercialization and product lifecycle challenges, from Svoboda Capital Partners. Lumanity is a portfolio company of the private equity firm, Arsenal Capital Partners. The terms of the acquisition were not disclosed.

The addition of Clarion strengthens Lumanity’s global consulting practice, bringing significant scale in the U.S. and complementing Lumanity’s existing experts in both the U.S. and Europe. Clarion and Lumanity’s combined capabilities create a global leader in the development and execution of successful commercialization strategies for biopharma companies’ increasingly complex asset portfolios.

Clarion’s deep scientific and commercial expertise throughout the product lifecycle and in nearly all therapeutic categories has allowed it to partner effectively with clients to tackle mission-critical strategic challenges at the asset, portfolio, and enterprise level. More specifically, Clarion works with clients to:

  • Evaluate the potential for early-stage assets and portfolios, especially in markets undergoing disruption,
  • Shape products and markets to enable successful product introduction, and,
  • Evolve functional and organizational capabilities to address the rapidly changing requirements for new product commercialization and value demonstration.

Jon Williams, the CEO of Lumanity, said, “Clarion is an exceptional addition to Lumanity. Clarion’s impressive team, specialized capabilities, and strong client relationships, significantly strengthen our ability to support the commercialization of our clients’ assets, ensuring patients get access to the right treatments.”

“We look forward to joining forces with Lumanity on our next chapter of growth,” stated Tom Murtagh, Co-founder of Clarion. “We believe Lumanity shares a similar mission-oriented culture and commitment to its clients and its employees. Together, we are eager to disrupt standard thinking regarding commercialization choices and build a more sustainable model to deliver true innovation to the healthcare ecosystem.”

Lumanity was formed by bringing together the expertise and capabilities of several exceptional organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, Innovative Edge, and Endpoint Outcomes. The addition of Clarion further enhances Lumanity’s unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject matter experts, and proven problem solvers with advanced clinical, scientific, and functional capabilities.

SVB Securities served as a financial advisor to Lumanity in the transaction.

About Lumanity

Lumanity applies incisive thinking and decisive action to cut through complex situations and deliver transformative outcomes to accelerate and optimize access to medical advances. By transforming data and information into real-world insights and evidence, Lumanity powers successful commercialization and empower patients, providers, payers, and regulators to take timely and decisive action. With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, its 1,200+ experts work with nearly all the top pharmaceutical and more than 100 biotech companies around the world. Turning aspiration into reality, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of 80 brands and new indications, and numerous award-winning product campaigns every year. For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn

About Clarion

Clarion is a life sciences strategy and organizational consultancy that works together with its clients to envision, craft, and enable growth through scientific and commercial innovation and leadership. Across therapeutic categories, Clarion collaborates deeply with its clients to tackle their most complex cross-functional business challenges and decisions throughout the product and company lifecycle. From start-up to global multinational companies, Clarion helps assemble and deliver on inspired strategies that require creativity, insight, and collaboration. Clarion builds leaders in the life sciences. Based in Boston, Massachusetts, Clarion was founded in 2003. For more information, visit www.clarionhealthcare.com and follow us on Instagram and LinkedIn.

About Svoboda Capital Partners

Svoboda Capital Partners is a Chicago-based private equity firm with over $400 million of capital under management. Founded in 1998, Svoboda identifies, invests in, and helps build excellent businesses in its targeted business niches of business services and value-added distribution. The firm typically makes investments of $10 to $20 million per company in partnership with management teams.

CONTACT for Lumanity:
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com

Categories: News

Tags:

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

Arsenal Capital Partners

rsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares

November 7, 2022

Princeton, N.J.- Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare companies, has committed to make a new $449M investment in Certara. Arsenal currently owns approximately 4% of common shares outstanding and will acquire approximately 30M additional shares from funds controlled by EQT Private Equity (“EQT”), at a price of $15 per share. Upon closing of the transaction, which is subject to HSR regulatory approval, Arsenal will own approximately 22% of diluted shares outstanding.

Arsenal is deeply familiar with Certara’s value proposition for all stakeholders. The firm previously held a majority stake in the company before selling a controlling interest to EQT in 2017. Arsenal continued to maintain a minority equity interest both before and after Certara’s initial public offering in 2020.

In a separate agreement with the company, Arsenal has agreed to a two-year lock-up prohibiting any sale of the newly purchased shares without company approval, reflecting Arsenal’s commitment to being a long-term shareholder. Arsenal will also have the right, subject to maintaining certain ownership percentages, to nominate up to two board members, including current board member Stephen McLean. Following the closing of the transaction, Arsenal Operating Partner David Spaight is expected to join the board, and current board members Eric Liu and Ethan Waxman of EQT will step down from the board.

“We are pleased to further enhance our long-term-oriented shareholder base via a significant new investment from Arsenal,” said William F. Feehery, Chief Executive Officer of Certara. “Arsenal has been invested in Certara for almost a decade, is confident in the critical role of biosimulation within drug discovery and development, and shares in our strategic vision for the business. I also want to thank EQT for its leadership and strategic partnership since 2017, highlighted by the company’s IPO in 2020.”

Stephen McLean, a Senior Partner of Arsenal, said, “This transaction reflects our long-term advocacy for, and conviction in, the strategic importance of biosimulation in drug development. It also reflects our belief in the long-term prospects of Certara, our admiration for William Feehery’s leadership, and our trust in the entire Certara management team. We look forward to our continued partnership with Certara and to further supporting its efforts to enable more efficacious development of therapies and cures for human disease.”

Eric Liu, Partner, Head of North American Private Equity, and Co-Head of the Global Healthcare Sector Team at EQT, added, “EQT is proud to have been part of Certara’s remarkable journey during the last five years. We would like to thank the management team for their trusted partnership. EQT is confident that Arsenal will continue to be a great shareholder as Certara builds on its strong momentum, and we look forward to the company’s continued success.”

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com

Jackie Schofield
Prosek Partners
Pro-Arsenal@prosek.com

Categories: News

Tags:

Corus grows in Spain with the acquisition of two laboratories in Seville and Madrid

Careventures

Corus added to its network the Manuel Peña Capuz laboratory in Seville and the Villadental center in Madrid, located in San Sebastián de los Reyes.

Corus goes on and on. The Spanish group of dental laboratories continues with its commitment to growth in Spain and has acquired two new laboratories in Seville and Madrid. The company based in Sant Cugat del Vallès (Barcelona) has integrated into its network the Manuel Peña Capuz laboratory, a center specialising in dental prostheses located on Martínez de Medina street in Seville. The facility works with fixed, removable and combined prostheses. In addition, Corus has integrated into its network the Villadental laboratory, directed by Ignacio Villafáñez, which is located on Calle Gomera in San Sebastián de los Reyes (Madrid). The two facilities work together to offer their products to clinics and professionals in the dental sector.

Corus has recently strengthened its position in Northern Europe with the acquisition of Nordentic.

Corus is a Barcelona-based company specialised in dental prosthetics and orthodontics. Since its creation in 2015, the company has integrated dental prosthetic laboratories distributed between Spain, France and Portugal, mainly. Corus operates as an integrated digital platform where dentists can interact with the local laboratory and the patient at the same time, guaranteeing prescription traceability and the necessary information to realise products and services tailored to the patient. Corus’ main shareholders are Careventures and Quadrum Capital. The former is a Private Equity firm with offices in Barcelona and Brussels, specialised in investments in healthcare services. Careventures has accumulated more than one hundred transactions in ten different countries, with more than 6,000 employees in the companies it manages. Quadrum Capital is a Private Equity firm with offices in Woerden and Almelo, both in the Netherlands.

The company aims to close 2022 with a turnover of €180m.

Last August, Corus acquired Nordentic, a Scandinavian company that operates in the same sector, but in Sweden, Norway and Denmark. The purchase followed another operation that the Spanish company carried out in March 2022, when Corus acquired the Dutch company Signadens. With all the operations carried out, Corus will together manage a network of more than 60 laboratories and more than 1,500 employees. The company started the year aiming for a turnover of €100m euros in 2022, but now the forecast is around €180m. This would mean doubling the turnover with which it started the year, with €73m.

The link to the article can be found here.

Categories: News

Tags:

Nordic Capital and Five Arrows to sell The Binding Site, a global leader in specialty diagnostics

Nordic Capital

The Binding Site has grown significantly under Nordic Capital’s and Five Arrows’ ownership, creating an industry leader in oncology testing for detection and monitoring of Multiple Myeloma

OCTOBER 31 2022

Nordic Capital and Five Arrows have entered into a definitive agreement to sell The Binding Site, a global leader in specialty diagnostics, to Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science. The transaction is valued at GBP 2.25 billion. Since the acquisition of The Binding Site in 2011, the business has made an impressive transformation from a founder-led research-based organisation to a leader in delivering innovative medical solutions that improve the detection, diagnosis and management of blood cancers and immune system disorders.

The transformation has been achieved by significant investments into its technology, growth and with a dedicated focus on R&D to support research and drive improved clinical outcomes. Since 2011, The Binding Site has grown fivefold with revenues amounted to approximately GBP 200 mn in 2022 and more than 40 million tests sold on a global scale. The Binding Site’s Freelite® offering is widely recommended for Multiple Myeloma diagnosis and monitoring across multiple stages of the disease by many major clinical diagnosis and treatment guideline publications. By joining Thermo Fisher Scientific, the world leader in serving science, The Binding Site will be even better positioned to accelerate scientific discovery and expand its product offering.

“We are proud to have partnered with The Binding Site. Their cutting-edge technology and innovative specialty diagnostic solutions improve millions of patient lives globally. During Nordic Capital’s ownership the company has experienced strong growth and transformation, achieved by a dedicated focus on R&D investment, commercial focus and global expansion. We are grateful to The Binding Site team, for their dedication and for building strong scientific foundations which support the changing needs of patients and clinicians. This transaction marks the culmination of a very successful partnership, a successful outcome for Nordic Capital’s investors and the start of an exciting next phase for the Binding Site,” says Dr Raj Shah, Partner and Head of Healthcare, Nordic Capital Advisors and Jonas Agnblad, Partner, Nordic Capital Advisors and Board Member, The Binding Site.

“The Binding Site has always been a pioneer in the field of protein diagnostics, which has helped create an exceptional following with key opinion leaders in cancer treatment and strong customer loyalty. It has been a great privilege for us to work with Stefan and his management team and we have every confidence that The Binding Site will continue to thrive under the ownership of Thermo Fisher Scientific,” says Javed Khan, Managing Partner of Five Arrows.

“We have enjoyed and benefitted greatly from our long-standing partnership with Nordic Capital and Five Arrows and their sustained active support over the years to help us to realise our vision and deliver for our customers and patients. Their supportive approach to investments in R&D, coupled with deep insights and expertise in healthcare has resulted in a consistent long-strategy focused on growth. This transaction marks the beginning of a new and exciting chapter for The Binding Site,” says Stefan Wolf, CEO, The Binding Site.

Nordic Capital has been the majority owner of The Binding Site since 2011 when it completed the acquisition together with Five Arrows. The transaction, which is expected to be completed in the first half of 2023, is subject to customary closing conditions, including regulatory approvals.

Media contact:

Nordic Capital
Katarina Janerud, Communications Manager
Nordic Capital Advisors
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

 

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”

 

About Nordic Capital

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested close to EUR 22 billion in 130 investments. The committed capital is principally provided by international institutional investors such as pension funds.  Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com

 

About Five Arrows

Five Arrows is the alternative assets arm of Rothschild & Co and has €22 billion of AuM with offices in Paris, London, New York, Los Angeles, San Francisco and Luxembourg. With over €8 billion of assets under management, the corporate private equity business of Five Arrows is focused on investing in companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology-enabled business services and healthcare.

https://www.rothschildandco.com/en/merchant-banking/corporate-private-equity/

 

About The Binding Site

The Binding Site is a global specialist protein diagnostics company engaged in the research, development, manufacture and distribution of innovative tests used for the detection of cancers and immune disorders. It is a business centered on the idea of working in collaboration with its partners and customers to lead the way in specialised medical diagnostics. The Company is headquartered in Birmingham, UK and has a direct presence in over 23 countries, employing over 1,100 people worldwide. Read more on www.bindingsite.com

Categories: News

Tags:

August Equity announces significant investment in OneTouch, including acquisition of tri.x

August Equity

August Equity has announced its investment into OneTouch. Led by founder and CEO Dermot Clancy, OneTouch is an end-to-end care management software platform that supports the management of all care delivery needs, from client and carer scheduling, HR management, incident tracking, care planning and family communications for care providers across Ireland and the UK.

August’s investment provides funding for the business to support its ambitious growth plans, including investment into sales and marketing, further product development and funding for strategic acquisitions that bring highly complementary software and service offerings to the group to benefit OneTouch’s customer base of care providers, including homecare agencies, care homes, local authorities and specialist care providers. Dr Sati Sian joins the board as Chairman, bringing a depth of experience across the technology and healthtech space.

As part of the investment, OneTouch has acquired Signis Limited, which trades under the tri.x brand and has been carved out from BGF-backed Antser Holdings. Tri.x is the market leader in the provision of effective online adult and children’s social care procedures solutions, supporting all Local Authorities and a number of independent care providers across England, and provides a highly complementary content-based offering to OneTouch’s software platform.

OneTouch and tri.x together offer care organisations a wealth of content, functionality and digital tools to support carers to deliver the highest quality care to clients, communicate easily with clients and families and ensure that carers have the maximum visibility and flexibility over their work schedules.

Christian Dubé and Katie Beckingham, August Equity, commented, “We are delighted to have invested in OneTouch and tri.x, bringing together two unique and valuable businesses in the care sector, at a time when digitisation and technology is at the forefront of care delivery. At August, we have a long history of investing in social care businesses and understand the challenges faced by the sector and the benefit that a truly end-to-end care management platform and compliance platform can bring to care providers. We look forward to working with Dermot, Sati and the team to continue the strong growth of the business to date.”

Dermot Clancy, CEO of OneTouch, said, “We are really excited for the next stage of OneTouch’s growth with August’s backing and experience scaling businesses and delivering acquisitions. Bringing tri.x into the OneTouch group provides our customers with a fantastic resource of policies, procedures and best-practice handbooks, which is a great addition to the software offering and functionality that we have built to support them in delivering the highest quality and most efficient care to their clients.”

Dr Sati Sian, Chairman of OneTouch, added, “Given the already proven unique assets that OneTouch and tri.x bring to the care sector, combined with August’s successful history of supporting businesses in the sector, I am really looking forward to working with Dermot and his excellent management team in driving OneTouch to its next stage of growth.”

August Equity was advised by CMS (legal), KPMG (financial and tax), CIL (commercial), Lockton (insurance), and Xaeus Blue (technology).

Categories: News

Tags:

Gimv partners with the founders of Les Psy Réunis group to develop a leading outpatient mental care provider in Switzerland

GIMV

Topic: Investment

Gimv has invested alongside the founders of the Les Psy Réunis. This investment is aimed at accelerating the development of a network of mental care centers across Switzerland and strengthening its organisation to face the upcoming regulatory changes in the sector. 

Created in 2018 by Doctors Elizabeth and Andrei Cicotti, Les Psy Réunis has established a strong position in the outpatient mental care space in Switzerland. In 2021, the Group’s psychiatrists and psychologists have provided more than 50,000 consultations to patients.

Les Psy Réunis is one of the most dynamic players in its market. Under the leadership of its founders, it has set up a model of group practices preserving the independence of doctors whilst matching the effectiveness of more integrated models. Since inception, it has experienced very strong organic growth and aims to consolidate its market through an efficient operating organisation based on two pillars, quality of care and a strong appeal to treatment providers.

Today the group runs five centres in Geneva and has more than 80 therapists. In partnership with leading doctors, it plans to pursue its growth in its core market as well as in strategic adjacencies (eg. mental care at home, training, etc.) through both organic and external growth. To achieve this, the Group intends to draw on its talents, further develop the current infrastructure and implement its digitisation plan. In order to lead this effort, it has recently strengthened its management team through the appointment of Cédric Alfonso, former CEO of the Clinique Générale-Beaulieu, and of Apolline Eberlé who has extensive experience in supporting healthcare institutions in their digital transformation.

“Choosing the Gimv team as a partner was natural, as we share common values and the same vision for Les Psy Réunis. We were convinced by their knowledge of the healthcare sector, and their ability to provide support in strengthening the organisation and implementing a build-up strategy”, explains Andrei Cicotti, CEO of Les Psy Réunis.

“The Healthcare team has identified the strong demand-supply gap in the outpatient mental care space and has been looking to invest in players able to be part of “the solution”. We are convinced that Les Psy Réunis, created by visionary entrepreneurial doctors, is part of the answer. Our expertise in the consolidation of healthcare subsectors and implementation of ambitious digital and ESG roadmaps, combined with our long-term vision, will be key levers to realize our shared ambition. We are very proud to have been selected by the founders to support them in their development plans” says Gautier Lefebvre, Healthcare Partner at Gimv.

Kevin Klein, Healthcare Principal at Gimv adds: “Les Psy Réunis in our view constitutes an ideal platform for creating a major player in outpatient mental health care in Switzerland. The Group relies on a top-notch team which has demonstrated that its concept delivers excellent results for all stakeholders and is ready for rollout on a larger scale”.

No details are given on the financial side of the operation.

 

Read the full document

English – French – Dutch
 

Gimv

Karel Oomsstraat 37, 2018 Antwerpen, Belgium

www.gimv.com

Categories: News

Tags:

EQT Life Sciences announces strategic alliance of its portfolio company iSTAR Medical with AbbVie

eqt

Alliance will provide opportunity for AbbVie to further expand its diverse eye care portfolio and provide additional treatment options for glaucoma patients.

Collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates goal to bring MINIject to more patients globally.

Deal terms include a $60M upfront payment to iSTAR Medical.

iSTAR Medical to continue development and commercialization of the MINIject device up to completion of the U.S. PMA study.

EQT Life Sciences today announced that AbbVie (NYSE: ABBV) and iSTAR Medical SA have entered into a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical’s development and commercial efforts for MINIject®, as well as provide an opportunity to expand AbbVie’s eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and stent offerings. iSTAR Medical is a portfolio company of the LSP Health Economics Fund 2 managed by the EQT Life Sciences team.

MINIject® received Conformité Européenne (CE) marking approval to commercialize in European countries in the last quarter of 2021 and launched commercially in select European countries in early 2022. iSTAR Medical is currently enrolling a U.S. Pre-Market Approval study (STAR-V) to enable commercialization in the U.S.

“As a leading company in eye care with a commitment to a broad and diverse portfolio from the front to the back of the eye, along with our global footprint and infrastructure in glaucoma, we are well-positioned to support bringing this MIGS offering to patients and glaucoma specialists through this strategic alliance,” said Michael Robinson, M.D, Vice President, Global Therapeutic Area Head of Eye Care, AbbVie. “This alliance with iSTAR Medical is an important step as we continue to be an innovator in glaucoma by maximizing the value of interventional approaches throughout the treatment paradigm.”

“Today’s announcement is validation of the transformational role of MINIject in the treatment of glaucoma,” said Michel Vanbrabant, Chief Executive Officer, iSTAR Medical. “Our commitment has always been to enable more glaucoma patients globally to be treated effectively in a minimally-invasive manner with our MINIject® MIGS device, and this alliance accelerates that goal, especially in the United States. We will benefit from AbbVie’s strong global experience and knowledge base already established in glaucoma, and we are excited to be working with such a world class team.”

Under the terms of the agreement, iSTAR Medical will receive a $60M non-dilutive upfront payment and will continue to develop and commercialize MINIject® until completion of the STAR-V clinical study. AbbVie will hold the exclusive right to acquire iSTAR Medical and lead subsequent global development and commercialization of the MINIject device. If AbbVie exercises the right to acquire iSTAR, the stockholders of iSTAR Medical would also be eligible to receive additional contingent payments of up to $475M in a closing payment and upon achievement of certain predetermined milestones.

iSTAR Medical will remain an independent company through the completion of the STAR-V study. This financing will support the continued development and commercialization of MINIject®, including ongoing clinical studies and further enhancements to the technology. SVB Securities LLC acted as financial advisor to iSTAR Medical.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie’s acquisition of Allergan plc (“Allergan”), failure to promptly and effectively integrate Allergan’s businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Contact
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Categories: News

Tags:

Meridian Adhesives Group Acquires Design Polymerics

September 9, 2022

Houston, TX- Meridian Adhesives Group (Meridian) announced today the acquisition of Design Polymerics, a manufacturer of high-performance sealants, adhesives, insulation mastics and indoor air quality products.

Design Polymerics was acquired by Lyle Davis in 1993, and the company has grown steadily over the past three decades. Through the company’s dynamic product line, commitment to sustainability, technical expertise and close partnerships with its customers, Design Polymerics has become a leader in the HVAC, Insulation and Indoor Air Quality industries.

“We are very excited about joining the Meridian team,” said Davis. “We believe Design Polymerics found the perfect partner to continue its growth and technical experience in our industry. We look forward to implementing manufacturing capabilities throughout the United States to better serve our customers while introducing new, innovative products to remain a leader in the HVAC, Insulation and IAQ industries.”

Design Polymerics will join Meridian’s Industrial Product Assembly Division alongside American Sealants, Inc.

“We are thrilled to have Design Polymerics join the Industrial Product Assembly Division of Meridian,” said Andrew Zaremba, President of the division. “We are looking forward to adding their proven product line to our portfolio and extending our reach into the HVAC market through Design Polymeric’s reputation as an industry leader in this space.”

This addition brings Meridian’s portfolio to 17 acquisitions and comes a day after American Securities’ announcement of the acquisition of Meridian from Arsenal Capital Partners.

“Design Polymerics is an excellent addition to our portfolio,” said Daniel Pelton, CEO of Meridian. “Management has built a solid adhesives company with a proven track record in the HVAC market, and I am excited to have Design Polymerics on board as we extend the Meridian footprint into new markets. This is the first of a new series of acquisitions to come with our new ownership American Securities, and we are thankful for their support as we continue to aggressively advance in the adhesives market.”

About Meridian Adhesives Group
Meridian Adhesives Group is a leading manufacturer of high-value adhesive technologies. With a broad portfolio of dynamic solutions, Meridian serves the electronics, infrastructure, and industrial (flooring, packaging, and product assembly) markets. The group’s operations are located in the Americas, EMEA, and Asia, with a multitude of sales/service offices worldwide that are positioned to serve Meridian’s global customer base. For more information, visit https://meridianadhesives.com.

Categories: News

Tags:

Balance Point Announces its Investment in Apollo Intelligence, LLC

Balance Point Capital
Westport, CT, September 8, 2022 – Balance Point Capital Advisors, LLC (“Balance Point”), in conjunction with its affiliated fund, Balance Point Capital Partners V, L.P., is pleased to announce an investment in Apollo Intelligence, LLC (“Apollo”, or “the Company”).  Balance Point provided debt capital as part of a flexible financing solution as part of Frazier Healthcare Partners’ (“Frazier”) acquisition of the Company.
Founded in 2019, and headquartered in Watertown, MA, Apollo is a market leader in life science research and insights.  Apollo’s unique integration of healthcare stakeholder access, powerful tech-enabled analytic tools, and domain expertise enables global healthcare organizations to efficiently develop, refine, and deliver life-changing innovations.  Through the Company’s proprietary, global, healthcare professional (HCP) panels, agile research platform, and expert services, Apollo delivers valuable insights that help life science companies make timely, informed decisions.
“We are thrilled to support an established industry leader such as Apollo, and we are excited to partner for the first time with Frazier Healthcare Partners,” said Balance Point Managing Partner Seth Alvord.
“Apollo holds a clear leadership position in today’s life sciences research landscape, and we believe that Frazier adds significant experience and resources to help Apollo grow,” added Nathan Elliott, Senior Managing Director at Balance Point Capital.
Daniel S. Fitzgerald, CEO and president of Apollo, said, “We are happy to have Balance Point as part of our team.  They are constructive, know our industry well, and support our mission to accelerate health innovation to improve life, as well as our strategy for growth.”
About Balance Point
Balance Point is an alternative investment manager focused on the lower middle market. With approximately $1.7 billion in assets under management, Balance Point invests debt and equity capital in select lower middle market companies across a variety of investment vehicles. Balance Point takes a long-term, partnership approach to investing and is committed to building lasting relationships with its partners, management teams and intermediaries.  Balance Point is a registered investment advisor. Further information is available at www.balancepointcapital.com.
About Apollo Intelligence
Apollo Intelligence’s mission is to accelerate health innovation to improve life. In 2019, Apollo launched with the acquisition of InCrowd, the pioneer of real-time, automated insights for the life science industry. To complement InCrowd and strengthen its global reach, in 2020, Apollo acquired Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions. Apollo provides access to 2 million healthcare stakeholders worldwide—including physicians, patients, caregivers, and allied healthcare professionals. Apollo’s 250+ employees support top global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. For more information about Apollo, please visit our website at www.apollointelligence.net.

Categories: News

Tags:

ONCAP Partners with Ideal Dental

TORONTO, SACRAMENTO, July 5, 2022 – ONCAP today announced it has made a significant investment in Ideal Dental Management Partners (“Ideal Dental” or the “Company”), in partnership with its affiliated doctors.
Ideal Dental is a specialty dental service organization focused on providing business and administrative services to specialty dental service providers. The Company partners with doctors who independently diagnose and treat their patients, providing orthodontic, pedodontics, oral surgery and other therapeutic services. Together, they deliver exceptional care through the latest innovation and technology and the best patient experience possible – treating every patient and their family members with empathy and respect.

“Ideal Dental is devoted to clinical and operational excellence and we’re thrilled to partner with such an exceptional operating team and group of distinguished doctors,” said Aly Hadibhai, a Managing Director with ONCAP. “We see an opportunity to accelerate the Company’s growth plan through organic and inorganic initiatives and look forward to working together in this next phase of its evolution.”

“ONCAP has an impressive track record working with multi-site consumer-facing businesses operating in fragmented industries, making it the right partner for us,” Alejandra Salonga, Vice President of Operations with Ideal Dental. “I am confident they will help fulfill Ideal Dental’s vision of becoming the premier specialty dental services organization in the Western U.S.”

The investment was made by ONCAP IV, Onex Corporation’s (TSX:ONEX) $1.1 billion private equity fund. The terms of the transaction are not being disclosed at this time.

About ONCAP
ONCAP is the mid-market private equity platform of Onex. In partnership with operating company management teams, ONCAP invests in and builds value in North American headquartered small- and medium-sized businesses that are market leaders and possess meaningful growth potential. For more information on ONCAP, visit its website at www.oncap.com.
Onex is an investor and asset manager that invests capital on behalf of Onex shareholders and clients across the globe. Formed in 1984, we have a long track record of creating value for our clients and shareholders. Onex’ two primary businesses are Private Equity and Credit. In Private Equity, we raise funds from third-party investors, or limited partners, and invest them, along with Onex’ own investing capital, through the funds of our private equity platforms, Onex Partners and ONCAP. Similarly, in Credit, we raise and invest capital across several private credit, public credit and public equity strategies. Our investors include a broad range of global clients, including public and private pension plans, sovereign wealth funds, insurance companies and family offices. In addition, through our private wealth platform, we service high net worth clients in Canada. In total, as of March 31, 2022 Onex has $49.2 billion in assets under management, of which $8.2 billion is Onex’ own investing capital. With offices in Toronto, New York, New Jersey, Boston and London, Onex and its experienced management teams are collectively the largest investors across Onex’ platforms. Onex is listed on the Toronto Stock Exchange under the symbol ONEX. For more information on Onex, visit its website at
www.onex.com. Onex’ security filings can also be accessed at www.sedar.com.

About Ideal Dental Management Partners
Ideal Dental Management Partners was built on the shared passion and mission to provide exceptional dental care through the latest innovation and technology, and the belief that everyone deserves to have the confidence and positivity that comes from a healthy, beautiful smile. Ideal Dental Management Partners and the independent specialty dental care practices it supports operate 28 locations on the West Coast through its dental specialty brands. Combined, the brands have provided high-quality dental specialty care to more than 200,000 patients. Ideal Dental Management Partners is headquartered at 3075 Beacon Blvd., West Sacramento, CA 95691.

For Further Information:
Onex
Jill Homenuk
Managing Director – Shareholder
Relations and Communications
Tel: +1 416.362.7711
Ideal Dental
Alejandra Salonga
Vice President of Operations
info@idealdentalmp.com

Categories: News

Tags: